Survodutide

Survodutide is a synthetic peptide classified as a GLP-1/Glucagon dual agonist. This means it is designed to activate both the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. While currently unregulated and not FDA approved, it is being investigated for its potential therapeutic effects, primarily in the areas of weight management and metabolic disorders. Our trust verification system assigns Survodutide a trust score of 87.0/100, earning it a grade of A, based on its research score (94.0) and safety score (80.0).

The mechanism of action of Survodutide involves mimicking the effects of both GLP-1 and glucagon. GLP-1 receptor activation is known to stimulate insulin secretion, suppress glucagon secretion, slow gastric emptying, and promote satiety. Glucagon receptor activation, on the other hand, increases energy expenditure and promotes lipolysis (fat breakdown). The dual agonism is theorized to provide a synergistic effect, potentially leading to greater weight loss and improved metabolic control compared to GLP-1 receptor agonists alone. Research indicates that Survodutide acts through circumventricular organs in the brain, activating neuronal regions associated with appetite regulation, as demonstrated in a study published in *Molecular Metabolism*.

The current research landscape for Survodutide is robust, with 31 clinical trials registered and 65 research papers published. Boehringer Ingelheim is the primary sponsor of several Phase 3 clinical trials, including the SYNCHRONIZE™ program. The SYNCHRONIZE™ - CVOT trial (n=5533) is evaluating the cardiovascular safety of Survodutide in individuals with overweight or obesity. The LIVERAGE™ trials (n=1800 and n=1590) are investigating its efficacy in treating non-alcoholic steatohepatitis (NASH/MASH) with moderate to advanced liver fibrosis and cirrhosis, respectively. Two other Phase 3 trials focused on weight loss in individuals with (n=755) and without (n=726) diabetes have also been conducted, with the latter already completed. Baseline characteristics of participants in the SYNCHRONIZE™-1 trial were detailed in a *Diabetes Obesity Metabolism* publication. These trials are crucial for determining the efficacy and safety profile of Survodutide across diverse patient populations.

The safety profile of Survodutide is under close scrutiny in ongoing clinical trials. While the overall trust score is relatively high, the safety score of 80.0 reflects the need for continued monitoring. FDA adverse event data currently shows only 1 total report, with no serious classifications. Reported adverse events include acute kidney injury, acute myocardial infarction, and vomiting. It is important to note that this data is limited and may not fully represent the potential risks associated with Survodutide use, especially in larger populations or with long-term exposure.

Given its potential for weight loss and metabolic benefits, Survodutide is primarily used by individuals seeking to manage their weight or improve their body composition. This includes individuals with overweight or obesity, as well as those with related metabolic disorders such as type 2 diabetes and NASH/MASH. However, it is crucial to emphasize that Survodutide is currently unregulated and not FDA approved, meaning its use is not sanctioned by regulatory bodies.

The future of Survodutide hinges on the outcomes of ongoing Phase 3 clinical trials and subsequent regulatory review processes, which will determine its ultimate role in the management of obesity and related metabolic conditions.